Directorio

We are doing this study to evaluate the safety and effectiveness of a drug called isatuximab when it is used in combination with lenalidomide and dexamethasone at lower doses. We want to know if this low dose combination can help patients with multiple myeloma achieve a better response while causing fewer or less severe side effects.

We are doing this study to better understand the unmet sexual health concerns of young adult male cancer survivors.

We are doing this study to learn more about variants in people's genes that cause cells in the back of the eye to function incorrectly and lead to a process called "retinal degeneration."

We are doing this study is to compare the effects of Urolithin A and placebo (an inactive substance with no medicinal properties) on the biological composition of the prostate in men with prostate cancer. In this study, you will have an equal chance of either taking Urolithin A or placebo.

We are doing this study to collect information about our state-of-the-art methods to care for the bladder and kidneys of babies born with spina bifida. We want to compare the results of these methods with other hospitals around the country that are following the same guidelines to protect the bladder and kidney health of infants with spina bifida. We and the other centers following these guidelines will regularly evaluate the outcomes of this care and modify the methods accordingly.

We are doing this study to test the feasibility and acceptability of an experimental communication device. This device was invented by a team from the Duke Pratt School of Engineering and is intended to help people with ALS and those who help take care of them.

We are doing this study to learn how we can help and improve care for patients that have had a transplant.

We are doing this study to find out the most preferred method among lung cancer patients for being connected to remote patient monitoring (RPM) devices. RPM devices are instruments that a patient can use to measure their own weight and vital signs. We want to find out if patients have an easier, more efficient time setting up these devices by using a virtual interface or with the assistance of a human agent.